417 related articles for article (PubMed ID: 33177239)
1. Structural basis for GLP-1 receptor activation by LY3502970, an orally active nonpeptide agonist.
Kawai T; Sun B; Yoshino H; Feng D; Suzuki Y; Fukazawa M; Nagao S; Wainscott DB; Showalter AD; Droz BA; Kobilka TS; Coghlan MP; Willard FS; Kawabe Y; Kobilka BK; Sloop KW
Proc Natl Acad Sci U S A; 2020 Nov; 117(47):29959-29967. PubMed ID: 33177239
[TBL] [Abstract][Full Text] [Related]
2. Structural basis of peptidomimetic agonism revealed by small- molecule GLP-1R agonists Boc5 and WB4-24.
Cong Z; Zhou Q; Li Y; Chen LN; Zhang ZC; Liang A; Liu Q; Wu X; Dai A; Xia T; Wu W; Zhang Y; Yang D; Wang MW
Proc Natl Acad Sci U S A; 2022 May; 119(20):e2200155119. PubMed ID: 35561211
[TBL] [Abstract][Full Text] [Related]
3. Two distinct domains of the glucagon-like peptide-1 receptor control peptide-mediated biased agonism.
Lei S; Clydesdale L; Dai A; Cai X; Feng Y; Yang D; Liang YL; Koole C; Zhao P; Coudrat T; Christopoulos A; Wang MW; Wootten D; Sexton PM
J Biol Chem; 2018 Jun; 293(24):9370-9387. PubMed ID: 29717000
[TBL] [Abstract][Full Text] [Related]
4. Novel Site-Specific Fatty Chain-Modified GLP-1 Receptor Agonist with Potent Antidiabetic Effects.
Zhong X; Chen Z; Chen Q; Zhao W; Chen Z
Molecules; 2019 Feb; 24(4):. PubMed ID: 30795583
[TBL] [Abstract][Full Text] [Related]
5. Partial agonism improves the anti-hyperglycaemic efficacy of an oxyntomodulin-derived GLP-1R/GCGR co-agonist.
Pickford P; Lucey M; Rujan RM; McGlone ER; Bitsi S; Ashford FB; Corrêa IR; Hodson DJ; Tomas A; Deganutti G; Reynolds CA; Owen BM; Tan TM; Minnion J; Jones B; Bloom SR
Mol Metab; 2021 Sep; 51():101242. PubMed ID: 33933675
[TBL] [Abstract][Full Text] [Related]
6. Genetic and biased agonist-mediated reductions in β-arrestin recruitment prolong cAMP signaling at glucagon family receptors.
Jones B; McGlone ER; Fang Z; Pickford P; Corrêa IR; Oishi A; Jockers R; Inoue A; Kumar S; Görlitz F; Dunsby C; French PMW; Rutter GA; Tan T; Tomas A; Bloom SR
J Biol Chem; 2021; 296():100133. PubMed ID: 33268378
[TBL] [Abstract][Full Text] [Related]
7. Functional GLP-1R antibodies identified from a synthetic GPCR-focused library demonstrate potent blood glucose control.
Liu Q; Garg P; Hasdemir B; Wang L; Tuscano E; Sever E; Keane E; Hernandez AGL; Yuan TZ; Kwan E; Lai J; Szot G; Paruthiyil S; Axelrod F; K Sato A
MAbs; 2021; 13(1):1893425. PubMed ID: 33706686
[TBL] [Abstract][Full Text] [Related]
8. Molecular insights into ago-allosteric modulation of the human glucagon-like peptide-1 receptor.
Cong Z; Chen LN; Ma H; Zhou Q; Zou X; Ye C; Dai A; Liu Q; Huang W; Sun X; Wang X; Xu P; Zhao L; Xia T; Zhong W; Yang D; Eric Xu H; Zhang Y; Wang MW
Nat Commun; 2021 Jun; 12(1):3763. PubMed ID: 34145245
[TBL] [Abstract][Full Text] [Related]
9. Cryo-electron microscopy structure of the glucagon receptor with a dual-agonist peptide.
Chang R; Zhang X; Qiao A; Dai A; Belousoff MJ; Tan Q; Shao L; Zhong L; Lin G; Liang YL; Ma L; Han S; Yang D; Danev R; Wang MW; Wootten D; Wu B; Sexton PM
J Biol Chem; 2020 Jul; 295(28):9313-9325. PubMed ID: 32371397
[TBL] [Abstract][Full Text] [Related]
10. Acylation of the Incretin Peptide Exendin-4 Directly Impacts Glucagon-Like Peptide-1 Receptor Signaling and Trafficking.
Lucey M; Ashik T; Marzook A; Wang Y; Goulding J; Oishi A; Broichhagen J; Hodson DJ; Minnion J; Elani Y; Jockers R; Briddon SJ; Bloom SR; Tomas A; Jones B
Mol Pharmacol; 2021 Oct; 100(4):319-334. PubMed ID: 34315812
[TBL] [Abstract][Full Text] [Related]
11. Positive Allosteric Modulation of the Glucagon-like Peptide-1 Receptor by Diverse Electrophiles.
Bueno AB; Showalter AD; Wainscott DB; Stutsman C; Marín A; Ficorilli J; Cabrera O; Willard FS; Sloop KW
J Biol Chem; 2016 May; 291(20):10700-15. PubMed ID: 26975372
[TBL] [Abstract][Full Text] [Related]
12. Rapid selection of a novel GLP-1/GIP dual receptor agonist with prolonged glycemic control and weight loss in rodent animals.
Wu Y; Ji T; Lv J; Wang Z
Life Sci; 2020 Sep; 257():118025. PubMed ID: 32598933
[TBL] [Abstract][Full Text] [Related]
13. Human GLP-1 receptor transmembrane domain structure in complex with allosteric modulators.
Song G; Yang D; Wang Y; de Graaf C; Zhou Q; Jiang S; Liu K; Cai X; Dai A; Lin G; Liu D; Wu F; Wu Y; Zhao S; Ye L; Han GW; Lau J; Wu B; Hanson MA; Liu ZJ; Wang MW; Stevens RC
Nature; 2017 Jun; 546(7657):312-315. PubMed ID: 28514449
[TBL] [Abstract][Full Text] [Related]
14. The dual GCGR/GLP-1R agonist survodutide: Biomarkers and pharmacological profiling for clinical candidate selection.
Thomas L; Martel E; Rist W; Uphues I; Hamprecht D; Neubauer H; Augustin R
Diabetes Obes Metab; 2024 Jun; 26(6):2368-2378. PubMed ID: 38560764
[TBL] [Abstract][Full Text] [Related]
15. Discovery of an Orally Efficacious Positive Allosteric Modulator of the Glucagon-like Peptide-1 Receptor.
Willard FS; Wainscott DB; Showalter AD; Stutsman C; Ma W; Cardona GR; Zink RW; Corkins CM; Chen Q; Yumibe N; Agejas J; Cumming GR; Minguez JM; Jiménez A; Mateo AI; Castaño AM; Briere DA; Sloop KW; Bueno AB
J Med Chem; 2021 Mar; 64(6):3439-3448. PubMed ID: 33721487
[TBL] [Abstract][Full Text] [Related]
16. Structural Determinants of Binding the Seven-transmembrane Domain of the Glucagon-like Peptide-1 Receptor (GLP-1R).
Yang D; de Graaf C; Yang L; Song G; Dai A; Cai X; Feng Y; Reedtz-Runge S; Hanson MA; Yang H; Jiang H; Stevens RC; Wang MW
J Biol Chem; 2016 Jun; 291(25):12991-3004. PubMed ID: 27059958
[TBL] [Abstract][Full Text] [Related]
17. Exenatide upregulates gene expression of glucagon-like peptide-1 receptor and nerve growth factor in streptozotocin/nicotinamide-induced diabetic mice.
Gumuslu E; Cine N; Ertan M; Mutlu O; Komsuoglu Celikyurt I; Ulak G
Fundam Clin Pharmacol; 2018 Apr; 32(2):174-180. PubMed ID: 29091313
[TBL] [Abstract][Full Text] [Related]
18. Differential Requirement of the Extracellular Domain in Activation of Class B G Protein-coupled Receptors.
Zhao LH; Yin Y; Yang D; Liu B; Hou L; Wang X; Pal K; Jiang Y; Feng Y; Cai X; Dai A; Liu M; Wang MW; Melcher K; Xu HE
J Biol Chem; 2016 Jul; 291(29):15119-30. PubMed ID: 27226600
[TBL] [Abstract][Full Text] [Related]
19. Running on mixed fuel-dual agonistic approach of GLP-1 and GCG receptors leads to beneficial impact on body weight and blood glucose control: A comparative study between mice and non-human primates.
Elvert R; Herling AW; Bossart M; Weiss T; Zhang B; Wenski P; Wandschneider J; Kleutsch S; Butty U; Kannt A; Wagner M; Haack T; Evers A; Dudda A; Lorenz M; Keil S; Larsen PJ
Diabetes Obes Metab; 2018 Aug; 20(8):1836-1851. PubMed ID: 29938884
[TBL] [Abstract][Full Text] [Related]
20. Cryo-EM structure of the dual incretin receptor agonist, peptide-19, in complex with the glucagon-like peptide-1 receptor.
Johnson RM; Zhang X; Piper SJ; Nettleton TJ; Vandekolk TH; Langmead CJ; Danev R; Sexton PM; Wootten D
Biochem Biophys Res Commun; 2021 Nov; 578():84-90. PubMed ID: 34547628
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
